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Abstract
Background: Internalized stigma is defined as individuals’ acceptance of negative stereotypes created by society and then their
alienation from society. Psoriasis is a dermatological disease that affects the quality of life. The study evaluated the internalized
stigma and quality of life of patients diagnosed with psoriasis.
Methods: This cross sectional study enrolled 222 patients. Data were collected using the internalized stigma scale and the
dermatology life quality index questionnaires. Data were analyzed using the Cronbach’s alpha.
Results: The internalized stigma score of the patients was 78.41 ± 23.14, and the quality of life score was 12.30 ± 5.67. Stigmatization
and quality of life were affected by patients’ physical, psychological, and social lives (p < 0.05).
Conclusions: Patients’ internalized stigma level was high, their quality of life was low, and their quality of life decreased as the
internalized stigma level increased. Furthermore, the internalized stigma level of the patients who suffered more from psoriasis
was higher, but their quality of life was lower than those who suffered less.
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INTRODUCTION

quality of life of patients.2 Even a small plaque lesion in
psoriasis may be enough for patients to feel stigmatized.
Researchers have also explained that the quality of life of
patients with psoriasis is as important as those with other
chronic diseases because they experience high levels of
stigma. Moreover, a study reported that quality of life and
stigma interact with each other in patients with psoriasis;
thus, they should be considered together.1

Psoriasis is a dermatological disease where stigmatization
is common.1,2 The World Health Organization (WHO)
prepared a global report to reduce the disease burden in
patients with psoriasis, enable them to combat stigma
and exclusion, and increase their healthcare and social
participation. In 2014, the WHO declared psoriasis a
noncommunicable disease to increase awareness of its
stigma.3 Internalized stigma is the feeling of stigma
experienced by the individual despite not being
stigmatized by the society.4 Internalized stigma is defined
as individuals’ acceptance of negative stereotypes created
by society and subsequent withdrawal from society, with
feelings such as worthlessness and shame.1,5,6 Psoriasis,
which is a visible disease, leads to feeling shy and
embarrassed, thinking one has a defect, and having a
negative body image, fear, loneliness, stress, and loss of
self-confidence.7,8 Patients experience hopelessness
about the symptoms and treatment. Psoriasis is a
stigmatizing disease and causes higher levels of
stigmatization than other dermatological diseases.9

Lesions, itching, and flaking seen in patients with psoriasis
decrease their quality of life.10 Although psoriasis is
benign, it is a lifelong skin disease. Experience of relapses
decreases the quality of life of patients with psoriasis. 11
Psoriasis affects the physiological and psychological life of
the patients, causing a decrease in social functionality and
deterioration of interpersonal relationships.12,13
No studies have discussed the internalized stigma and
quality of life of patients with psoriasis living in a city
located in the east of Turkey. This study investigated the
internalized stigma, quality of life, and affecting factors in
patients with psoriasis.

Researchers have stated that psoriatic lesions may be an
important determinant of psychosocial functioning and
that the lesions may cause stigma and decrease the

METHODS
The research was conducted in accordance with the
principles of the Declaration of Helsinki. The patients were
informed about the study, and their consent was obtained.
The study was approved by the ethics committees of the
Ataturk University Faculty of Health Sciences (No. 2018-2/6)
and of the hospital where the study was conducted (No.
42190979-000-E.1800130824).
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This descriptive and cross-sectional study was enrolled
patients with psoriasis who were admitted to Ataturk
University Research and Application Hospital Dermatology
Outpatient Clinic between March 2018 and February 2019.
Between these dates, 240 patients were interviewed. Of
these patients, 18 were excluded because they did not
agree to participate in the study; finally, the study enrolled
222 patients. Psoriasis patients aged ≥18 years, those who
had adequate communication, and those who agreed to
participate were included in the study. In the power
analysis, the statistical power of the research was 0.99 at
95% confidence interval and 0.05 significance level,
showing that the sample size was sufficient.14 Study data
were collected using the internalized stigma scale and
dermatology life quality index questionnaires.
The researcher-prepared questionnaire was in line with the
literature.12,15 Before starting the study, a pilot study was
conducted with 10 patients. The final questionnaire
contained 21 questions, including sociodemographic
characteristics of patients with psoriasis such as age, sex,
education, and employment status and disease-related
variables such as the duration of the illness and effect of the
disease on psychological status, family, work, and social life.
The internalized stigma scale was developed by Ritsher et
al. to measure the subjective stigma experience of
individuals.16 The scale can be used for psoriasis and mental
illness. The Turkish validity and reliability study of the scale
for patients with psoriasis was performed by Alpsoy et al.17
The scale consists of 29 questions. Responses to the items
in the internalized stigma scale are given according to a 4point Likert-type scale, including “strongly disagree” (1
point), “disagree” (2 points), “strongly agree” (3 points), and
“strongly disagree” (4 points). The total scale score ranges
from 29 to 116. High scale scores indicate that more severe
internalized stigma. The Cronbach’s alpha value in the
reliability study of the scale conducted with patients with
psoriasis was 0.89.17 In the present study, the Cronbach’s
alpha value of the scale was 0.98.
The dermatology life quality index, a self-administered
questionnaire widely used in dermatological diseases,
consists of 10 questions addressing the issues most
complained about related to the quality of life over the last
week. The questions cover the following topics: symptoms
and emotions (questions 1 and 2), daily activities (questions
3 and 4), hobbies (questions 5 and 6), work and school
(question 7), personal relationships (questions 8 and 9), and
treatment (question 10). In the scale, nine questions are
answered according to a Likert-type scale (0, not at all; 1, a
little; 2, a lot; and 3, very much). Question 7 is answered
“yes” or “no.” In question 7, if the answer is “yes,” it is scored
as 3; however, if the answer is “no,” it is scored as 0. The
total scale score is the sum of the scores of each question.
The maximum and minimum scores of the scale are 30 and
0, respectively. As the score increases, the quality of life
decreases. Öztürkcan et al. performed the Turkish validity
Makara J Health Res.
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and reliability study of the scale, and Cronbach’s alpha was
0.87 in the validity and reliability study.18 In the present
study, the Cronbach’s alpha value of the scale was 0.87.
Data were analyzed using SPSS Statistics for Windows,
version 17 (SPSS Inc., Chicago, IL, USA). Numbers,
percentages, mean, and standard deviation were used in
the data analysis. Skewness and kurtosis were used to
examine whether the data were normally distributed.
Independent samples t-test, one-way analysis of variance,
least significant difference, Pearson’s and Spearman’s
correlation test were used for data analysis.
RESULTS
Table 1 shows age, disease period, life quality, and
internalized stigma of the patients. The mean internalized
stigmatization score and quality of life score of the
patients were 78.41 ± 23.14 and 12.30 ± 5.67, respectively
(Table 1). The majority of the participants were women
(51.8%), married (60.4%), higher education graduates
(54.1%), unemployed (55.4%), and living in the city center
(55%). Of the patients, 28.3% visited the hospital for
treatment and 52.3% for their symptoms, 40.5% did not
receive treatment regularly, 20.7% had another disease,
15.8% had psoriatic arthritis, and 35.6% had a family
member with psoriasis. Of the patients, 46.8% were
smokers, and patients reported that their psychological
(80.2%), physical (91.9%), and sexual health (14.4%), family
(23.4%), work (17.6%), and social life (69.8%) were affected
(Table 2).
The internalized stigma and quality of life scores were
significantly higher in patients who visited the hospital for
treatment and symptoms, did not receive treatment
regularly, had other illnesses and psoriatic arthritis, had a
family member with psoriasis, were smokers, and reported
that psychological, physical and sexual health, family,
work, and social life were affected (p < 0.05) (Table 3).
A significant difference was found between the reasons
for the patients visit to the hospital for treatment and the
internalized stigma and quality of life scores (p < 0.05).
Further analysis showed that the mean internalized
stigma and quality of life scores for those who visited the
hospital for treatment and symptoms were higher than
for those visiting for follow-up (Table 3).
A significant moderate positive relationship was found
between the internalized stigma and quality of life scores
(p < 0.05) (Table 4). The mean patient age and disease
duration were 36.95 ± 12.42 and 11.77 ± 10.86,
respectively. A significant positive correlation was found
between age and disease duration and internalized
stigma and mean quality of life scores (p < 0.05).
The internalized stigma scores of those who were female,
married, unemployed, and lived in villages were higher
December 2022 | Vol. 26 | No. 3
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than those of their counterparts, but the difference was
not significant. As the education level of the patients
decreased, the mean internalized stigma score increased,
but the difference was not significant. No significant
association was found between sex, place of residence,
and marital, educational, and employment statuses with
the mean quality of life scores (p > 0.05).
TABLE 1. Age, disease period, life quality, and internalized
stigma of the patients
Variables
Age, years (min–max, 18–68)
Disease period, years (min–max, 1–50)
Life quality (min–max, 0–26)
Internalized stigma (min–max, 29–109)

Mean ± SD
36.95 ± 12.42
11.77 ± 10.86
12.30 ± 5.67
78.41 ± 23.14

TABLE 2. Patients’ characteristics (N = 222)
Frequency
(N)

Variables

Percentage
(%)

Sex
Female

115

51.8

Male

107

48.2

134

60.4

88

39.6

Literate

10

4.5

Primary school

20

9.0

Secondary school

24

10.8

120

54.1

48

21.6

99

44.6

123

55.4

Marital status
Married
Single
Educational status

High school
University
Employment status
Employed
Unemployed
Place of residence
Village

21

9.4

District

79

35.6

122

55

City

TABLE 2. Continued
Frequency
(N)

Variables

Percentage
(%)

Reason for visiting hospital
Symptoms

116

52.3

Follow-up

43

19.4

Treatment

63

28.3

Yes

132

59.5

No

90

40.5

35
187

15.8
84.2

118
104

53.2
46.8

176
46

79.3
20.7

79
143

35.6
64.4

178
44

80.2
19.8

52
170

23.4
76.6

39
183

17.6
82.4

155
18

69.8
8.1

204
18

91.9
8.1

32
190

14.4
85.6

Receiving regular treatment

Psoriatic arthritis
Yes
No
Smoking
No
Yes
Another disease
No
Yes
Family member with psoriasis
Yes
No
Psychological health
Affected
Not affected
Family life
Affected
Not affected
Business life
Affected
Not affected
Social life
Affected
Not affected
Physical health
Affected
Not affected
Sexual health
Affected
Not affected

TABLE 3. Comparison of patients’ characteristics, internalized stigma, and life quality scores (N = 222)
Variables
Sex
Female
Male
Marital status
Married
Single
Educational status
Literate
Primary school
Secondary School
High school
University
Employment status
Employed
Unemployed
Makara J Health Res.

Internalized stigma
Mean ± SD

p

Life quality
Mean ± SD

p

80.23 ± 22.89
76.44 ± 23.35

0.223a

12.20 ± 5.44
12.52 ± 5.91

0.575a

78.69 ± 22.81
77.97 ± 23.76

0.819a

12.48 ± 5.61
12.03 ± 5.76

0.569a

86.70 ± 22.72
83.65 ± 19.30
78.25 ± 22.70
77.51 ± 23.48
76.81 ± 24.28
77.64 ± 23.57
79.02 ± 22.87

0.609b

0.658a

15.00 ± 7.06
13.60 ± 5.73
12.25 ± 6.10
11.99 ± 5.24
12.00 ± 6.14
12.09 ± 5.49
12.74 ± 5.82

0.434b

0.620a
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TABLE 3. Continued
Internalized stigma
Mean ± SD

Variables
Place of residence
Village
District
City
Reason for visiting hospital
Symptoms
Follow-up
Treatment
Receiving regular treatment
Yes
No
Psoriatic arthritis
Yes
No
Smoking
No
Yes
Another disease
No
Yes
Family member with psoriasis
Yes
No
Psychological health
Affected
Not affected
Family life
Affected
Not affected
Business life
Affected
Not affected
Social life
Affected
Not affected
Physical health
Affected
Not affected
Sexual health
Affected
Not affected

Life quality
Mean ± SD

p

p

82.10 ± 23.05
79.96 ± 22.21
76.76 ± 23.78

0.473b

13.52 ± 5.72
12.30 ± 5.24
12.09 ± 5.93

0.566b

81.72 ± 21.80
64.51 ± 24.06
81.79 ± 21.65

<0.001b

12.88 ± 5.50
8.51 ± 4.65
13.83 ± 5.53

<0.001b

75.17 ± 24.29
83.14 ± 20.57

0.009a

11.65 ± 5.75
13.26 ± 5.43

0.038a

87.49 ± 21.29
76.71 ± 23.13

0.009a

15.63 ± 5.45
11.68 ± 5.50

<0.001a

74.09 ± 23.55
83.30 ± 21.76

0.003a

11.31 ± 5.69
13.42 ± 5.45

0.005a

75.22 ± 24.06
90.61 ± 13.70

<0.001a

11.55 ± 5.60
15.17 ± 4.98

<0.001a

82.67 ± 20.24
76.05 ± 24.35

0.041a

13.37 ± 4.68
11.71 ± 6.08

0.037a

85.79 ± 18.63
48.55 ± 13.36

<0.001a

13.82 ± 4.98
6.16 ± 3.85

<0.001a

94.94 ± 6.33
73.35 ± 24.05

<0.001a

17.81 ± 3.93
10.62 ± 5.01

<0.001a

93.36 ± 9.78
75.22 ± 23.92

<0.001a

19.05 ± 4.21
10.86 ± 4.84

<0.001a

85.39 ± 14.53
52.99 ± 19.01

<0.001a

14.67 ± 4.54
5.44 ± 5.04

<0.001a

81.06 ± 21.48
48.33 ± 20.27

<0.001a

12.91 ± 5.32
5.44 ± 5.04

<0.001a

91.66 ± 13.66
76.17 ± 23.68

<0.001a

16.78±4.67
11.55±5.47

<0.001a

Bold values: Results are significant if p < 0.05.
aIndependent sample t-test; bOne-way analysis of variance (ANOVA).

TABLE 4. Correlation of patients’ characteristics, internalized stigma, and life quality scores
Variables
Age, years (min–max, 18–68)
Disease Period, years (min–max, 1–50)
Life quality (min–max, 0–26)
Internalized stigma (min–max, 29–109)

r
0.181
0.167
0.745

p
0.007a
0.013b
<0.001a

r
0.155
0.137

p
0.021a
0.041b

0.745

<0.001a

Bold values: Results are significant if p < 0.05.
aPearson’s correlation analysis; bSpearman’s correlation analysis.

DISCUSSION
In this study, patients with psoriasis were to have high
levels of internalized stigmatization and low quality of life.
Makara J Health Res.

In addition, as the internalized stigma increased, the
quality of life decreased. Internalized stigmatization is the
feeling of stigmatization experienced by an individual,
despite not being stigmatized by society.4 Internalized
December 2022 | Vol. 26 | No. 3
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stigma is defined as individuals’ acceptance of negative
stereotypes created by society and subsequent withdrawal
from society, with feelings such as worthlessness and
shame.1,5,6,19 Internalized stigmatization causes a decrease
in self-esteem and life satisfaction, an increase in
depression and tendency to commit suicide, and difficulty
in coping with the disease.15
This study determined that patients with psoriasis have
high levels of internalized stigma and low quality of life. In
addition, as the internalized stigma increased, the quality
of life decreased. Studies conducted with patients with
psoriasis in various regions of Turkey, except the present
study, have high levels of internalized stigma but a low
quality of life. Similarly, the quality of life decreased as the
internalized stigma increased.15,17 Intense emotional and
psychosocial effects in patients with psoriasis cause
stigmatization.12 Patients with psoriasis who have lesions
in visible areas such as the face, nails, and scalp
experience high levels of stigma.17 Patients with psoriasis
have higher levels of stigma than patients with acne
vulgaris, atopic dermatitis, sun-damaged skin, eczema, or
fungal and viral skin infections. The same study also found
a relationship between the stigma subscale of the
internalized stigma and poor quality of life.9 The quality of
life is low in patients with psoriasis who hide their skin
symptoms and retreat from social environments and
people.2,5,20 Psoriasis causes a decrease in the quality of
life because of its physical, psychological, and social
effects.2 In line with these results, healthcare
professionals should provide necessary training and
support for patients with psoriasis to reduce internalized
stigma levels and improve their quality of life.
The physical health of a majority of the patients was
affected, and their internalized stigma level was high, and
their quality of life was low. In this study, 15.8% of the
patients had psoriatic arthritis and had similarly high
internalized stigma levels and low quality of life. The
physical health of patients who have pain, movement
limitation, skin involvement, and psoriatic arthritis was
negatively affected, and their quality of life was low. 10 A
study of patients with psoriasis found that 2.9% had
psoriatic arthritis and those with psoriatic arthritis had
higher levels of internalized stigma.15 Another study
comparing the effects of skin and joint symptoms in
psoriasis found that the feelings of depression, shame,
and guilt and the perception that others thought that the
disease was contagious were significantly higher in those
with skin symptoms.21,22 Health professionals can
contribute to improving the quality of life of patients by
reducing the physiological and psychological effects of
psoriasis.23
In this study, the psychological state of the majority of the
patients was affected, and their internalized stigma levels
were high, and their quality of life was low. However,
others report fewer psychological effects. A study
Makara J Health Res.

reported that 33% of their patients had depressive
symptoms and experienced guilt, rejection, and stigma4,
whereas another reported that 58% of their patients with
psoriasis felt ashamed of their appearance and 24%
experienced depression.24 In another study, 58.1% of the
patients with psoriasis had depression and higher
internalized stigma levels than those who suffered from
depression. Stigma leads to a feeling of humiliation,
defective thinking, having a negative body image, and low
self-esteem.7 Patients with psoriasis whose psychological
status is affected had low quality of life.25 Skin diseases
affecting appearance also influence interpersonal
relationships.26 A study suggested that health
professionals should provide the necessary training and
psychological and social support for patients with
psoriasis.27
Skin diseases affect social life and induced patients to feel
separate from society.9 In this study, the social life of the
majority of the patients was affected, their internalized
stigma level was high, and their quality of life was low.
Patients with psoriasis whose social life is affected, hide
their lesions, and avoid doing activities where their lesions
would appear have higher levels of stigma.28 A study
conducted with Polish patients with psoriasis reported
that the disease limited their social life and induced
patients to feel a higher level of internalized stigma.5
Psoriasis limits relationships in the family and among
friends, group activities, going to public places, and
participating in social activities. Patients with psoriasis
who limit their social activities in public areas such as
swimming, sunbathing, and going to the beach also have
a low quality of life.29 Patients with psoriasis feel
hopelessness and social withdrawal, which negatively
affects their quality of life.30
In this study, 23.4% of patients’ family life and 14.4% of
patients’ sexual life were affected, and these patients had
high levels of internalized stigma and low quality of life.
Moreover, the level of internalized stigma was high in
married and female participants, but the difference was
not significant. A study reported that married patients
with psoriasis experienced higher levels of internalized
stigma but sex did not affect internalized stigma.17 Stigma,
negative self-esteem, depression, ideas of suicide,
anxiety, and sexual dysfunction negatively affect the
family and friendship relations of patients with
psoriasis.22,29 Of the patients with psoriasis, 63% had at
least one genital involvement in their lifetime, and these
patients’ psychological condition deteriorated and their
quality of life decreased.31
In the present study, 17.6% of the patients’ business life
was affected, and their internalized stigma level was high,
and their quality of life was low, but this difference was
not significant. Psoriasis negatively affects the ability to
work and decreases productivity and quality of life.5 A
study reported that 12% of their patients with psoriasis
December 2022 | Vol. 26 | No. 3

Stigma and Life Quality in Psoriasis

were unemployed, and 92% of them could not work
because of psoriasis symptoms and psoriatic arthritis.9 In
another study, 60% of the patients with psoriasis quit their
jobs because of the illness, requested excessive sick leave
from their workplaces, and had low quality of life.25
In the present study, 35.6% of the patients had a family
member with psoriasis, and these people experienced
higher levels of stigma and lower quality of life. Another
study found that 32.8% of the participants had a family
member with psoriasis and their internalized stigma
levels were higher than those without an affected family
member.15 A study of Polish patients with psoriasis
determined that those who had a family member with
psoriasis understood psoriasis better and received more
support from their family members; thus, they coped with
the disease better.5
In the present study, 20.7% of the patients had another
disease. The internalized stigma level of these patients
was high, and their quality of life was low. Mental illnesses
such as depression and anxiety in patients with psoriasis
cause higher levels of stigmatization.7 Comorbidities such
as Crohn’s disease, cardiovascular, metabolic, and chronic
intestinal diseases, and psychological disorders in
patients with psoriasis create additional disease burden
and decrease the quality of life.3,32 Contrary to the present
study, a study reported that the presence of another
disease in patients with psoriasis did not affect
internalized stigma.15
In the present study, 40.5% of the patients did not receive
treatment regularly. These patients and those who visited
the hospital for their treatment and symptoms had high
levels of internalized stigma and low quality of life. In
psoriasis, compliance with the treatment is low, and the
internalized stigma level is high.15 Patients with psoriasis
are incompatible with treatment, unable to cope with
symptoms, have a negative body image, and withdraw
socially. In addition, patients who have no hope of
recovery, cannot cope with the symptoms, and do not
follow the treatment have a lower quality of life.30
Psychological problems are also common in patients with
psoriasis, and these problems increase cigaret and
alcohol consumption.30 In the present study, 46.8% of the
patients smoked, their internalized stigma level was
higher, and their quality of life was lower than those who
did not. Similarly, a study found that 43.2% of patients
with psoriasis smoked, their internalized stigma level was
high, and their quality of life was low.15 Another study
found a relationship between increased smoking and
antidepressant use and low quality of life in patients with
psoriasis.33

184

their internalized stigma level increases with an increasing
duration of illness.17 In contrast to this study, Alpsoy et
al.15 did not find a relationship between age and
internalized stigmatization in patients with psoriasis.
Patients with psoriasis at a young age, where physical
appearance is important, experience higher levels of
stigma than older patients.5 The quality of life of young
patients with psoriasis is lower, but as they get older, they
become more experienced in managing the symptoms
and more successful in dealing with these symptoms.21 A
study reported that as a recurrent disease, psoriasis
causes patients to feel despair, fail to plan for the future,
and a have decreased quality of life.11 Healthcare
professionals should provide necessary training and
support for patients with psoriasis, which should focus on
older patients with psoriasis and patients with chronic
disease.
The most important limitation of the study is the absence
of a control group. Data collection tools are limited to
patients’ self-reports. This study was limited to 222
patients with a diagnosis of psoriasis from a single center.
Thus, the results may not be generalizable to the entire
population with psoriasis.
CONCLUSIONS
Internalized stigmatization level was found to be high, and
the quality of life was low in patients with psoriasis. In
addition, as the internalized stigma level increased, the
quality of life decreased. Moreover, sociodemographic
characteristics, psychological, physical, and sexual health,
and family, work, and social life affect the internalized
stigma and quality of life of patients with psoriasis. Health
professionals should provide significant support to
patients by decreasing stigma and increasing the quality
of life. Health professionals play an important role in
preventing stigmatization by supporting patients with
psoriasis psychologically and socially and informing
society about psoriasis. Health professionals must make
significant contributions to preventing psoriasis to
worsen, ensuring that the individual is being active and
functional, decreasing the psychological effects of the
disease, and increasing the quality of life.
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